Related Party Transactions	12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	14. Related Party Transactions Astellas is an equity investor in the Company and considered a related party. During the years ended December 31, 2022, 2021 and 2020, the Company recorded license and development revenue related to collaboration agreements with Astellas of $32.5 million, $130.4 million, and $33.5 million, respectively. During the years ended December 31, 2022, 2021 and 2020, the Company also recorded drug product revenue from Astellas of $11.1 million, $3.2 million, and $4.3 million, respectively. See Note 3, Collaboration Agreements, License Agreement and Revenues, for details. The Company’s expense related to collaboration agreements with Astellas was immaterial for each of the three years ended December 31, 2022. As of December 31, 2022 and 2021, accounts receivable from Astellas were $1.5 million and $10.9 million, respectively. As of December 31, 2022 and 2021, total deferred revenue from Astellas were $40.3 million and $27.9 million, respectively. As of December 31, 2022, the amount due to Astellas was $63.9 million. As of December 31, 2021, the amount due to Astellas was immaterial. Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. See Note 4, Equity method investment - Variable Interest Entity, for details. For the years ended December 31, 2022 and 2021, the net product revenue from sales to Falikang were $71.2 million, and $35.6 million, respectively. See the Product Revenue, Net section in Note 3, Collaboration Agreements, License Agreement and Revenues, for details. The other income from Falikang were immaterial for each of the three years ended December 31, 2022. For the years ended December 31, 2022, 2021 and 2020, the investment income (loss) in Falikang was $1.6 million, $1.0 million, and $(0.2) million, respectively. As of December 31, 2022 and 2021, the Company’s equity method investment in Falikang were $5.1 million and $3.8 million, respectively. See Note 4, Equity method investment - Variable Interest Entity, for details. As of December 31, 2022, accounts receivable, net, from Falikang were $10.5 million. As of December 31, 2021, accounts receivable, net, from Falikang was zero. As of December 31, 2022, the total deferred revenue from Falikang was zero. As of December 31, 2021, the total deferred revenue from Falikang was $1.2 million.

Related Party Transactions

12 Months Ended

Dec. 31, 2021

14.

Related Party Transactions

Astellas is an equity investor in the Company and considered a related party. During the years ended December 31, 2022, 2021 and 2020, the Company recorded license and development revenue related to collaboration agreements with Astellas of $32.5 million, $130.4 million, and $33.5 million, respectively. During the years ended December 31, 2022, 2021 and 2020, the Company also recorded drug product revenue from Astellas of $11.1 million, $3.2 million, and $4.3 million, respectively. See Note 3, Collaboration Agreements, License Agreement and Revenues, for details.

The Company’s expense related to collaboration agreements with Astellas was immaterial for each of the three years ended December 31, 2022.

As of December 31, 2022 and 2021, accounts receivable from Astellas were $1.5 million and $10.9 million, respectively.

As of December 31, 2022 and 2021, total deferred revenue from Astellas were $40.3 million and $27.9 million, respectively.

As of December 31, 2022, the amount due to Astellas was $63.9 million. As of December 31, 2021, the amount due to Astellas was immaterial.

Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. See Note 4, Equity method investment - Variable Interest Entity, for details.

For the years ended December 31, 2022 and 2021, the net product revenue from sales to Falikang were $71.2 million, and $35.6 million, respectively. See the Product Revenue, Net section in Note 3, Collaboration Agreements, License Agreement and Revenues, for details. The other income from Falikang were immaterial for each of the three years ended December 31, 2022.

For the years ended December 31, 2022, 2021 and 2020, the investment income (loss) in Falikang was $1.6 million, $1.0 million, and $(0.2) million, respectively. As of December 31, 2022 and 2021, the Company’s equity method investment in Falikang were $5.1 million and $3.8 million, respectively. See Note 4, Equity method investment - Variable Interest Entity, for details.

As of December 31, 2022, accounts receivable, net, from Falikang were $10.5 million. As of December 31, 2021, accounts receivable, net, from Falikang was zero.

As of December 31, 2022, the total deferred revenue from Falikang was zero. As of December 31, 2021, the total deferred revenue from Falikang was $1.2 million.